(Q40889632)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8458108%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

review article

1 reference

title

Intravenous thrombolytic therapy in myocardial infarction: an analytical review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8458108%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8458108%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

author name string

N W Shammas

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8458108%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

P Fitzpatrick

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8458108%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

publication date

1 April 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8458108%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8458108%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8458108%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8458108%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

page(s)

283-292

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8458108%20AND%20SRC:MED&resulttype=core&format=json

Insights into the pathogenesis of acute ischemic syndromes

12 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

Streptokinase and recombinant tissue plasminogen activator (rt-PA) are equally effective in treating acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

Guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommitte

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

Selection of patients with acute myocardial infarction for thrombolytic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Effect of intravenous streptokinase on acute myocardial infarction: pooled results from randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Thrombolytic therapy: current status (1).

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Comparison of thrombolytic agents: selected hematologic, vascular and clinical events

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Prognosis after acute myocardial infarction in patients with and without residual anterograde coronary blood flow

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Influence of anterograde flow in the infarct artery on the incidence of late potentials after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Effects of early reperfusion in acute myocardial infarction on arrhythmias induced by programmed stimulation: a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Patency of the infarct-related coronary artery and ventricular geometry

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Heparin and infarct coronary artery patency after streptokinase in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

GISSI-2 and the heparin controversy

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS)

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Antithrombotic therapy after myocardial reperfusion in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Combination of calcium channel blocker and thrombolytic therapy in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Effects of intracoronary streptokinase and intracoronary nitroglycerin infusion on coronary angiographic patterns and mortality in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Late thrombolytic therapy preserves left ventricular function in patients with collateralized total coronary occlusion: primary end point findings of the Second Mount Sinai-New York University Reperfusion Trial

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Myocardial Infarction Triage and Intervention Project--phase I: patient characteristics and feasibility of prehospital initiation of thrombolytic therapy

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Optimal utilization of thrombolytic therapy for acute myocardial infarction: concepts and controversies

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS)

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trial

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Streptokinase in acute myocardial infarction. European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021

Multicenter patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction. The TEAM-2 Study Investigators.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160402

7 January 2021